|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01801 INNOVENT BIO
Nominal 
49.950 +3.350 (+7.189%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 9,421,888 | 51.817% | 6,206,070 | 4,556,380 | 4,269,729 | 3,843,819 |
| Cost of Sales | (1,510,210) | 32.910% | (1,136,266) | (930,990) | (505,337) | (387,761) |
| Gross Profit | 7,911,678 | 56.055% | 5,069,804 | 3,625,390 | 3,764,392 | 3,456,058 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (41,009) | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | (78,621) | -93.130% | (1,144,411) | (2,170,469) | (2,641,717) | (858,713) | |
| Taxation | (16,010) | -- | 116,498 | (8,801) | (87,038) | (139,708) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (94,631) | -90.794% | (1,027,913) | (2,179,270) | (2,728,755) | (998,421) | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (355,807) | 0.450% | (354,213) | (87,839) | (89,291) | (47,752) |
| Depreciation & Amortisation | 419,768 | 67.357% | 250,822 | 177,768 | 125,045 | 85,627 |
| Directors' Emoluments | -- | -- | 171,327 | 171,378 | 149,448 | 119,512 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | -6.000 | -90.909% | -66.000 | -146.000 | -188.000 | -74.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 0.095 | (1.288) | (1.391) | (0.227) |
| NBV per share ($) | 8.008 | -- | 7.724 | 6.993 | 7.065 | 6.259 |
| Remarks: | Real time quote last updated: 01/04/2025 12:19 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -94,631 |
| %Change | -90.794% |
| EPS / (LPS) | RMB -0.060 |
| NBV Per Share (¥) | RMB 8.008 |